DCIS Risk Biomarker on the Horizon

San Antonio—Researchers have completed the first of three planned validation studies for the Prelude DCIS test (PreludeDx). The tool is designed to help clinicians select patients with ductal carcinoma in situ (DCIS) for radiation therapy (RT).

“In the current study, the assay identified patients who have a clinically acceptable 10% risk for local failure at 10 years without radiation, but also the group we want to treat—patients who without radiation have a 30% risk of failure